Sera Prognostics (NASDAQ:SERA) CFO Austin Aerts Sells 5,263 Shares

Key Points

• Austin Aerts, CFO of Sera Prognostics, sold 5,263 shares of the company's stock for approximately $16,578, reducing his ownership by 1.81%.
• Sera Prognostics' stock price decreased by 2.2% on the same day, closing at $3.10, with a market cap of $116.78 million.
• Wall Street analysts downgraded Sera Prognostics from a "hold" to a "sell" rating, indicating a bearish outlook on the company's performance.

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) CFO Austin Aerts sold 5,263 shares of the firm's stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $3.15, for a total value of $16,578.45. Following the completion of the sale, the chief financial officer directly owned 285,585 shares in the company, valued at approximately $899,592.75. The trade was a 1.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Sera Prognostics Stock Down 2.2%

Shares of SERA stock traded down $0.07 during trading hours on Tuesday, hitting $3.10. 74,640 shares of the company's stock were exchanged, compared to its average volume of 104,642. Sera Prognostics, Inc. has a fifty-two week low of $1.37 and a fifty-two week high of $9.13. The firm has a market cap of $116.78 million, a P/E ratio of -3.65 and a beta of 1.00. The firm has a 50 day moving average of $2.77 and a two-hundred day moving average of $2.88.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.05. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million. Sera Prognostics had a negative net margin of 30,306.48% and a negative return on equity of 45.86%. On average, equities analysts forecast that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Institutional Trading of Sera Prognostics

Several large investors have recently bought and sold shares of the business. Corient Private Wealth LLC raised its holdings in Sera Prognostics by 73.9% in the 2nd quarter. Corient Private Wealth LLC now owns 100,000 shares of the company's stock valued at $277,000 after acquiring an additional 42,500 shares during the last quarter. Captrust Financial Advisors grew its position in shares of Sera Prognostics by 20.0% in the second quarter. Captrust Financial Advisors now owns 602,277 shares of the company's stock valued at $1,668,000 after purchasing an additional 100,366 shares in the last quarter. Qube Research & Technologies Ltd acquired a new stake in shares of Sera Prognostics in the second quarter valued at approximately $92,000. Riverview Capital Advisers LLC acquired a new stake in shares of Sera Prognostics in the second quarter valued at approximately $35,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Sera Prognostics during the second quarter worth approximately $188,000. Hedge funds and other institutional investors own 54.64% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen lowered shares of Sera Prognostics from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.